Improving Human Wellness Through Innovative Recombinant Protein Biotechnology
RIPT, an IP-based proprietary technology of InThera*enables
high-yield & rapid VLP production through the highly-efficient soluble expression of
target proteins in E. coli, where the yield of VLP formation is low.
In vitro self-assembly enables rapid production of high-quality homogeneous VLPs compared to other VLP production system.
Development and delivery of customized vaccines in a timely manner